Immortalized erythroid cells as a novel frontier for in vitro blood production: current approaches and potential clinical application
CF Cervellera, C Mazziotta, G Di Mauro… - Stem Cell Research & …, 2023 - Springer
Background Blood transfusions represent common medical procedures, which provide
essential supportive therapy. However, these procedures are notoriously expensive for …
essential supportive therapy. However, these procedures are notoriously expensive for …
Investigation on spontaneous abortion and human papillomavirus infection
M Tognon, A Tagliapietra, F Magagnoli, C Mazziotta… - Vaccines, 2020 - mdpi.com
Viral infections are considered to be risk factors for spontaneous abortion (SA). Conflicting
results have been reported on the association between Human Papillomavirus (HPV) and …
results have been reported on the association between Human Papillomavirus (HPV) and …
HPV vaccination and the prevention of genital warts and precancerous lesions—current evidence and evaluation
V Osmani, SJ Klug - Bundesgesundheitsblatt-Gesundheitsforschung …, 2021 - Springer
Humane Papillomviren (HPV) verursachen benigne und maligne Tumorerkrankungen.
Bisher wurden mehr als 200 HPV-Typen entdeckt, von denen aktuell 12 als Hochrisiko für …
Bisher wurden mehr als 200 HPV-Typen entdeckt, von denen aktuell 12 als Hochrisiko für …
Cobertura vacinal contra o Papilomavírus Humano (HPV) em meninas e adolescentes no Brasil: análise por coortes de nascimentos
LL Moura - 2019 - arca.fiocruz.br
Objetivo: Estimar a cobertura vacinal contra HPV em meninas e adolescentes nos
municípios brasileiros e identificar fatores associados com o alcance da cobertura …
municípios brasileiros e identificar fatores associados com o alcance da cobertura …
The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
TH Cheung, SSY Cheng, DC Hsu, QWL Wong… - Cost Effectiveness and …, 2021 - Springer
Abstract Introduction In Hong Kong (HK), a single-cohort vaccination program for 10–12-
year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types …
year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types …
Accounting for adverse events following immunization in economic evaluation: systematic review of economic evaluations of pediatric vaccines against …
K Doggen, AJ van Hoek, J Luyten - PharmacoEconomics, 2023 - Springer
Objectives Economic evaluations of vaccines should accurately represent all relevant
economic and health consequences of vaccination, including losses due to adverse events …
economic and health consequences of vaccination, including losses due to adverse events …
The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review
K Zhu, Y Tian, X Dong, BO Akinwunmi… - Archives of Gynecology …, 2022 - Springer
Purpose The aim of this study was to systematically review the cost-effectiveness of HPV
vaccination in Asia. Methods We performed a systematic review of papers indexed in …
vaccination in Asia. Methods We performed a systematic review of papers indexed in …
[HTML][HTML] HPV-Impfung zur Prävention von Genitalwarzen und Krebsvorstufen–Evidenzlage und Bewertung
V Osmani, SJ Klug - Bundesgesundheitsblatt …, 2021 - ncbi.nlm.nih.gov
Humane Papillomviren (HPV) verursachen benigne und maligne Tumorerkrankungen.
Bisher wurden mehr als 200 HPV-Typen entdeckt, von denen aktuell 12 als Hochrisiko für …
Bisher wurden mehr als 200 HPV-Typen entdeckt, von denen aktuell 12 als Hochrisiko für …
[HTML][HTML] Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia
A Wondimu, MJ Postma, M van Hulst - Vaccine, 2022 - Elsevier
Abstract Background In Ethiopia, cervical cancer is the second most common cancer among
women of the reproductive age group. Since 2018, the quadrivalent human papillomavirus …
women of the reproductive age group. Since 2018, the quadrivalent human papillomavirus …
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
Background A bivalent human papillomavirus vaccine (2vHPV) is currently used in the
Netherlands; a nonavalent vaccine (9vHPV) is also licensed. Research design and methods …
Netherlands; a nonavalent vaccine (9vHPV) is also licensed. Research design and methods …